The effects of PACAP and related peptides on leptin, soluble leptin receptor and resistin in normal condition and LPS-induced inflammation

Peptides

Volumn 30, Issue 8, 2009, Pages 1456-1459

  Yu, Rongjie ^a   Xie, Shanshan ^a   Chen, Jiansu ^a,b   Zhang, Ling ^a   Dai, Yun ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Leptin; LPS; PACAP; Resistin

Indexed keywords

ADIPOCYTOKINE; HORMONE RECEPTOR STIMULATING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; LEPTIN; LEPTIN RECEPTOR; LIPOPOLYSACCHARIDE; MAXADILAN; NEUROPEPTIDE; RESISTIN; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; INFLAMMATION; INFLAMMATORY DISEASE; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GROWTH SUBSTANCES; INFLAMMATION; INSECT PROTEINS; LEPTIN; LIPOPOLYSACCHARIDES; MALE; MICE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RANDOM ALLOCATION; RECEPTORS, LEPTIN; RESISTIN;

MUS;

EID: 67650357370     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.05.013     Document Type: Article

References (30)

1. Anderson P.D., Mehta N.N., Wolfe M.L., Hinkle C.C., Pruscino L., Comiskey L.L., Tabita-Martinez J., Sellers K.F., Rickels M.R., Ahima R.S., and Reilly M.P. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 92 (2007) 2272-2279
2. Bik W., Wolinska-Witort E., Baranowska-Bik A., Martynska L., Chmielowska M., and Baranowska B. PACAP38 inhibits adiponectin release. Neurol Endocrinol Lett 28 (2007) 166-169
3. Bik W., Wolinska-Witort E., Pawlak J., Skwarlo-Sonta K., Chmielowska M., Martynska L., Baranowska-Bik A., and Baranowska B. PACAP38 as a modulator of immune and endocrine responses during LPS-induced acute inflammation in rats. J Neuroimmunol 177 (2006) 76-84
4. Bokarewa M., Nagaev I., Dahlberg L., Smith U., and Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174 (2005) 5789-5795
5. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., Devaney J.M., Fishman C., Stamou S., Canos D., Zbinden S., Clavijo L.C., Jang G.J., Andrews J.A., Zhu J., and Epstein S.E. The potential role of resistin in atherogenesis. Atherosclerosis 182 (2005) 241-248
6. Delgado M., Abad C., Martinez C., Juarranz M.G., Leceta J., Ganea D., and Gomariz R.P. PACAP in immunity and inflammation. Ann NY Acad Sci 992 (2003) 141-157
7. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
8. Delgado M., Gomariz R.P., Martinez C., Abad C., and Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30 (2000) 3236-3246
9. Ganea D., and Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13 (2002) 229-237
10. Gourlet P., Vandermeers A., Vertongen P., Rathe J., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides 18 (1997) 1539-1545
11. Gourlet P., Vertongen P., Vandermeers A., Vandermeers-Piret M.C., Rathe J., De Neef P., Waelbroeck M., and Robberecht P. The long-acting vasoactive intestinal polypeptide agonist Ro25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18 (1997) 403-408
12. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., and Waschek J.A. International Union of Pharmacology, XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 (1998) 265-270
13. Holcomb I.N., Kabakoff R.C., Chan B., Baker T.W., Gurney A., Henzel W., Nelson C., Lowman H.B., Wright B.D., Skelton N.J., Frantz G.D., Tumas D.B., Peale Jr. F.V., Shelton D.L., and Hébert C.C. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19 (2000) 4046-4055
14. Huang L., Wang Z., and Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem 276 (2001) 6343-6349
15. Lago F., Dieguez C., Gómez-Reino J., and Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18 (2007) 313-325
16. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., and Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1 2 (2004) e45
17. Moro O., and Lerner E.A. Maxadilan the vasodilator from sand flies is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 272 (1997) 966-970
18. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gómez-Reino J.J., and Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579 (2005) 295-301
19. Sarraf P., Frederich R.A., Turner E.M., Ma G., Jaskowiak N.T., Rivet III D.J., Flier J.S., Lowell B.B., Fraker D.L., and Alexander H.R. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 185 (1996) 171-175
20. Sherwood N.M., Krueckl S.L., and McRory J.E. The origin and function of pituitary adenylate cyclase activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21 (2000) 619-670
21. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
22. Trayhurn P., and Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 33 (2005) 1078-1081
23. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., Zhu J., Dela Cruz F., Peng X., Chen H., Yung S.L., Hamren S., Livingston J.N., and Pan C.Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal, a potential therapy for type 2 diabetes. Diabetes 51 (2002) 1453-1460
24. Vaudry D., Gonzales B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: from structure to function. Pharmacol Rev 52 (2000) 269-324
25. Vaudry H., and Laburthe M. VIP, PACAP, and related peptides. From gene to therapy. Ann NY Acad Sci 1070 (2006)
26. Wei Y., and Mojsov S. Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann NY Acad Sci 805 (1996) 624-627
27. Wei Y., and Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 8 (1996) 811-817
28. Yu R.J., Hong A., Dai Y., and Gao Y. Intein-mediated rapid purification of recombinant human pituitary adenylate cyclase activating polypeptide. Acta Biochim Biophys Sin (Shanghai) 36 (2004) 759-766
29. Yu R., Yi T., Xie S., and Hong A. Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice. Peptides 29 (2008) 1347-1353
30. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432